An open-label pilot study of dose escalation of PEGASYS [peginterferon alfa-2a] on virological response in patients with chronic hepatitis C viral infection showing an early non-response to a standard course of PEGASYS plus ribavirin.

Trial Profile

An open-label pilot study of dose escalation of PEGASYS [peginterferon alfa-2a] on virological response in patients with chronic hepatitis C viral infection showing an early non-response to a standard course of PEGASYS plus ribavirin.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PINGU
  • Sponsors Roche
  • Most Recent Events

    • 06 Jun 2016 Study phase changed form phase 2 to phase 3
    • 06 Jun 2016 Status changed from completed to discontinued.
    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top